Search

everythinglearnresearchcommunity

for

Search:↓

Having asthma, atopic dermatitis, or Hashimoto's thyroiditis increases the risk of severe and long-lasting alopecia areata.

Yellow dots and short vellus hairs are the most common signs of Alopecia Areata (AA), and trichoscopy can help diagnose AA and track treatment progress.

Alopecia areata is unpredictable, with limited treatment effectiveness, especially in severe cases.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

People with Alopecia Areata are more likely to have autoimmune diseases, inflammatory diseases, and mental health issues like anxiety and depression.

New treatments for alopecia areata show promise but need ongoing use and have infection risks.

Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.

Janus kinase inhibitors are effective and safe for treating alopecia areata.

Hejie Shengfa Decoction may help treat alopecia areata by promoting hair growth and reducing inflammation, but more safety studies are needed.

Strainful life events may significantly trigger alopecia areata.

The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.

A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

Vitamin D deficiency is common in children with and without alopecia areata, and more research is needed.

Allergies, especially both seasonal and food, increase the risk of developing alopecia areata.

hsa-miR-193a-5p may help diagnose and treat alopecia areata.

High CRP levels could indicate vitamin D deficiency in people with alopecia areata.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

JAK inhibitors, PRP, and exosomes show promise for hair regrowth in Alopecia Areata.

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

Alopecia areata costs individuals about 3% of their income, with women, Asians, those with lower income, and more severe symptoms spending more.

Intralesional triamcinolone acetonide is better than PRP for treating scalp alopecia areata, leading to faster and more complete hair regrowth.

Alopecia areata significantly impacts patients' mental health and quality of life.

JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.

Low vitamin D levels are linked to severe and active alopecia areata.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

ADHD stimulant medications might be linked to a specific type of hair loss called Alopecia Universalis.

Oral cyclosporine works better than betamethasone minipulse therapy for treating Alopecia Areata.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.